N-(2'-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them

• US 5,137,918 A
• Filed: 10/09/1990
• Issued: 08/11/1992
• Est. Priority Date: 04/22/1986
• Status: Expired due to Term

• Current Assignee: Godecke AG
• Original Assignee: Goedecke Aktiengesellschaft
• Inventors: Vollmer, Karl-Otto, Weiershausen, Ute, Herrmann, Wolfgang, Satzinger, Gerhard
• Primary Examiner(s): ELMORE, CAROLYN
• Application Number:
  US07/594,592
• Time in Patent Office: 672 Days
• Field of Search: 564/157, 564/168, 514/616, 514/619
• US Class Current: 514/616
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07C 237/42 having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• CPC Class Codes: Y02P 20/55 Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention provides substituted N-(2'"'"'-aminophenyl)-benzamide derivatives useful for combating neoplastic diseases. The present invention also provides a process for the preparation of these benzamide derivatives, as well as pharmaceutical compositions containing them and methods for using them.

Claims

1. A compound of the formula ##STR7## wherein R is a lower acylamino group ##STR8## wherein X is hydrogen or a group of one to three carbon atoms unsubstituted or substituted by one or more hydroxyl groups.

2. A compound according to claim 1 and being 4-acetamino-N-(2'"'"'-aminophenyl)-benzamide.

3. A compound according to claim 1 and being 4-isobutyrylamino-N-(2'"'"'-aminophenyl)-benzamide.

4. A compound according to claim 1 and being 4-formylamino-N-(2'"'"'-aminophenyl)-benzamide.

5. A compound according to claim 1 and being 4-(β

-hydroxypropionylamino)-N-(2'"'"'-aminophenyl)-benzamide.

6. A compound according to claim 1 and being glycoloylamino-N-(2'"'"'-aminophenyl)-benzamide.

7. A pharmaceutical composition effective for treating mammary adenocarcinoma 16C comprising a therapeutically effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

8. A pharmaceutical composition effective for treating L1210 leukemia comprising a therapeutically effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

9. A pharmaceutical composition effective for treating colon adenocarcinoma comprising a therapeutically effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

10. A method for treating mammary adenocarcinoma 16C in mammals which comprises administering to a mammal in need thereof a pharmaceutical composition according to claim 7 in unit dosage form.

11. A method for treating L1210 leukemia in mammals which comprises administering to a mammal in need thereof a pharmaceutical composition according to claim 8 in unit dosage form.

12. A method for treating colon adenocarcinoma in mammals which comprises administering to a mammal in need thereof a pharmaceutical composition according to claim 9 in unit dosage form.